This case suggests that dose-adjusted T-DXd can achieve durable disease control with acceptable safety in a frail elderly patient with HR+/HER2-low breast cancer and pleural effusion, adding to the growing real-world evidence supporting the use of HER2-directed ADCs beyond traditional HER2-positive populations. Here, ERBB2 is linked to breast cancer.